Key result
Imatinib linked to complete resolution of eosinophilia and myeloid sarcoma in ~3 weeks.
Why the study?
Does imatinib mesylate improve clinical and cytogenetic outcomes in a patient with nonleukemic myeloid sarcoma with FIP1L1-PDGFRA rearrangement?
Case Report (n=1)
Does imatinib mesylate improve clinical and cytogenetic outcomes in a patient with nonleukemic myeloid sarcoma with FIP1L1-PDGFRA rearrangement?
Low-dose imatinib mesylate is highly effective in treating nonleukemic myeloid sarcoma with FIP1L1-PDGFRA rearrangement.
Answers are grounded in this paper and cite their sources.
May support imatinib consideration in rare eosinophilic myeloid sarcoma; leaves open need for prospective validation.
Rearrangement of the PDGFRA gene defines a distinct group of hematopoietic neoplasms that commonly present with persistent eosinophilia and are highly sensitive to low-dose imatinib mesylate treatment. Although rare cases of PDGFRA rearrangement-associated acute myeloid or lymphoblastic leukemia can occur, nonleukemic myeloid sarcoma has not been reported, and its sensitivity to imatinib treatment is unknown. Herein, we report a 31-year-old man with nonleukemic myeloid sarcoma and marked peripheral blood and bone marrow eosinophilia. Fluorescent in situ hybridization studies demonstrated that both bone marrow hematopoietic precursors and blasts of the myeloid sarcoma were positive for FIP1L1-PDGFRA rearrangement. The patient consequently received imatinib treatment at a dosage of 100 mg daily. After 3 weeks of therapy, his eosinophilia and myeloid sarcoma completely resolved, and at evaluation after 3 months he had attained bone marrow cytogenetic remission. To our knowledge, this is the first case of a nonleukemic myeloid sarcoma with the FIP1L1-PDGFRA rearrangement. Despite its aggressive clinical behavior attributed to myeloid sarcoma in general, the presence of PDGFRA rearrangement in this case conferred a high sensitivity to imatinib treatment and a favorable clinical outcome.
No takes yet. Share an insight, caveat, or question.
Chen et al. (2012) conducted a case report in Nonleukemic myeloid sarcoma with FIP1L1-PDGFRA rearrangement (n=1). Imatinib mesylate was evaluated on Resolution of eosinophilia and myeloid sarcoma, and bone marrow cytogenetic remission. Imatinib treatment led to complete resolution of eosinophilia and myeloid sarcoma within 3 weeks and bone marrow cytogenetic remission at 3 months.
Synapse has enriched 10 related papers. Consider them for comparative context: